April 17, 2018 / 1:17 PM / 3 months ago

BRIEF-Deciphera Pharma Expects To Start Late-Stage Study In Patients With Gastric Tract Tumors In Second Half Of 2018

April 17 (Reuters) - Deciphera Pharmaceuticals Inc:

* PRECLINICAL DATA DEMONSTRATE THAT DECIPHERA PHARMACEUTICALS’ DCC-2618 EXHIBITS BROADER INHIBITION PROFILE AGAINST PRIMARY AND SECONDARY DRUG-RESISTANT MUTATIONS IN GASTROINTESTINAL STROMAL TUMORS (GIST) COMPARED TO APPROVED AND INVESTIGATIONAL AGENTS

* DECIPHERA PHARMACEUTICALS - DCC-2618 DEMONSTRATED BROADEST PROFILE OF INHIBITION OF PRIMARY AND SECONDARY KIT MUTATIONS AND PRIMARY PDGFRΑ MUTATIONS

* DECIPHERA PHARMACEUTICALS INC - EXPECTS TO INITIATE A PHASE 3 REGISTRATION STUDY IN 2(ND) LINE GIST PATIENTS IN SECOND HALF OF 2018

* DECIPHERA PHARMACEUTICALS INC - EXPECTS TO REPORT TOP-LINE DATA FROM ONGOING INVICTUS STUDY IN 2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below